We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.75%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.07B
AUM Growth
-$181M
(-5.6%)
Cap. Flow
-$69.2M
Cap. Flow
% of AUM
-2.25%
Top 10 Holdings %
Top 10 Hldgs %
63.06%
Holding
43
New
2
Increased
11
Reduced
8
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$51.7M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$44.6M |
| 3 |
Globus Medical
GMED
|
+$39.6M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$32.6M |
| 5 |
Herbalife
HLF
|
+$26.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$80.7M |
| 2 |
Tenet Healthcare
THC
|
+$46.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$45.1M |
| 4 |
CONMED
CNMD
|
+$33.8M |
| 5 |
Zimmer Biomet
ZBH
|
+$27.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.08% |
| 2 | Consumer Staples | 1.66% |
| 3 | Consumer Discretionary | 0.75% |
| 4 | Miscellaneous | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Centene
CNC
$33.4B
| $27M | 0.88% |
400,000
| – | – |
|
27
Peloton Interactive
PTON
$2.13B
| $23.1M | 0.75% |
3,000,000
+2,250,000
| +300% | +$19.1M |
|
28
Collegium Pharmaceutical
COLL
$711M
| $22.6M | 0.73% |
1,050,000
| – | – |
|
29
OraSure Technologies
OSUR
$239M
| $21.3M | 0.69% |
4,250,000
| – | – |
|
|
BKDT
30
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
| $15.5M | 0.5% |
250,000
| – | – |
|
|
CVAC
31
DELISTED
CureVac
CVAC
| $15.2M | 0.5% |
1,462,500
+212,500
| +17% | +$1.9M |
|
32
Puma Biotechnology
PBYI
$477M
| $14.9M | 0.49% |
4,235,000
| – | – |
|
33
SkinHealth Systems
SKIN
$87.8M
| $14.6M | 0.48% |
1,750,000
+1,250,000
| +250% | +$13M |
|
34
Inogen
INGN
$138M
| $13.3M | 0.43% |
1,150,000
+175,000
| +18% | +$2.06M |
|
35
Glaukos
GKOS
$10.1B
| $11.4M | 0.37% |
160,000
-190,000
| -54% | -$10.9M |
|
36
Solid Biosciences
SLDB
$897M
| $7.43M | 0.24% |
1,418,439
| – | – |
|
|
CANO
37
DELISTED
Cano Health, Inc.
CANO
| $5.56M | 0.18% |
40,000
| – | – |
|
|
DVAX
38
DELISTED
Dynavax Technologies
DVAX
| $3.88M | 0.13% |
+300,000
| New | +$3.42M |
|
39
Align Technology
ALGN
$10.4B
| – | – |
-50,000
| Closed | -$16.7M |
|
|
40
CONMED
CNMD
$1.41B
| – | – |
-325,000
| Closed | -$33.8M |
|
41
PUT
Invesco QQQ Trust
QQQ
$474B
| – | – |
-1,000,000
| Closed | -$321M |
|
|
NSTG
42
DELISTED
NanoString Technologies, Inc.
NSTG
| – | – |
-1,500,000
| Closed | -$14.8M |
|
|
NUVA
43
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-600,000
| Closed | -$24.8M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Camber Capital Management held 43 positions worth $3.07B, down 5.6% from $3.25B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Camber Capital Management's Q2 2023 filing shows 2 new, 11 increased, 8 reduced and 5 closed positions. Its largest new stake was Medtronic: 600,000 shares worth $52.9M. The largest sale was Sanofi, an estimated $80.7M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
- Camber Capital Management's largest Q2 2023 buy was Medtronic: 600,000 shares worth $52.9M.
- Camber Capital Management added most to Teva Pharmaceutical Industries Limited in Q2 2023, an estimated $44.6M increase.
- Camber Capital Management's biggest Q2 2023 reduction was Sanofi, cutting an estimated $80.7M.
- Camber Capital Management fully exited CONMED in Q2 2023, selling an estimated $33.8M.
- Camber Capital Management's ten largest holdings make up 63% of its $3.07B portfolio in Q2 2023.
- Camber Capital Management opened 2 new positions and closed 5 in Q2 2023.
- Camber Capital Management's portfolio value fell 5.6% quarter-over-quarter to $3.07B.
Based on Camber Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.